BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap, no noise, just what matters.
Thursday, November 19, 2026
📌 TL;DR
The FDA approved Regeneron's Livsayis (cemdisiran), the first siRNA for generalized myasthenia gravis, dosed subcutaneously four times a year; the Phase 3 NIMBLE trial showed a 2.3 point placebo adjusted MG-ADL gain (p=0.0005), and the label carries a boxed warning with REMS only access.
It is the second new gMG medicine in three days: AstraZeneca's Klygefa (gefurulimab), a once weekly self administered C5 nanobody, was approved Monday on PREVAIL's 1.6 point MG-ADL benefit versus placebo (p<0.0001).
SELLAS priced its $150.0 million offering at $13.00 per share, 11,538,462 shares, closing November 20; the price is 32.1% below Tuesday's close (our arithmetic).
The FDA posted its ivonescimab complete response letter: benefits modest, a new trial needed, per BioPharma Dive; Summit had framed the rejection as a missing survival number.
Eli Lilly signed a Stipple Bio cancer alliance worth up to $5.9 billion, and Biogen paid over $32 million upfront to Trimtech for CNS penetrant protein degraders, both per BioPharma Dive.
Tape: SLS −6.3% into the pricing, MRK −3.9% post BTK kill, XBI flat.
⚡ Executive Takeaway
The most interesting thing about this week's two myasthenia gravis approvals is who made them. AstraZeneca built the infused C5 franchise, eculizumab and ravulizumab, and on Monday it approved the weekly autoinjector designed to replace them. That is the rare disease playbook at its most disciplined: cannibalize your own franchise before argenx or a biosimilar does it for you. Regeneron's answer on Wednesday was not a better antibody but a different modality entirely, an siRNA that shuts off C5 production for three months at a time. Neither company is arguing it has the strongest effect size in the disease; both are arguing they have the right number of needles per year. When convenience becomes the axis of competition, the incumbents with infusion chairs lose first, and the chronic disease playbook starts to look like consumer product management. Watch where Regeneron sets the price: four doses a year makes a per dose premium almost invisible to a payer comparing annual costs.
🧬 Two New Myasthenia Gravis Medicines in 72 Hours
The FDA approved Regeneron's Livsayis, the first siRNA for generalized myasthenia gravis and the only treatment dosed four times a year, two days after clearing AstraZeneca's weekly Klygefa autoinjector. REGN | AZN
Livsayis (cemdisiran) silences C5 production for three months at a time and delivered a 2.3 point placebo adjusted MG-ADL improvement at week 24 in NIMBLE (p=0.0005), with 76.6% of patients gaining at least 3 points versus 44.1% on placebo. The label carries a boxed warning for meningococcal infection and REMS only access, with vaccination required two weeks before the first dose. Klygefa (gefurulimab), a dual binding nanobody from Alexion approved Monday, is a once weekly self administered autoinjector that beat placebo by 1.6 MG-ADL points in the 260 patient PREVAIL trial. The two trials are not comparable head to head; the dosing columns are the point, and the same C5 target now spans a weekly home shot and a quarterly clinic visit.
Same target, two offers | Livsayis (Regeneron) | Klygefa (AstraZeneca) |
|---|---|---|
Dosing | Subcutaneous, four times a year | Weekly autoinjector, self administered |
Modality | siRNA, shuts off C5 production | Dual binding nanobody, blocks C5 |
MG-ADL vs placebo, own trial | +2.3 points, week 24 (NIMBLE) | +1.6 points, week 26 (PREVAIL) |
Access | Boxed warning, REMS restricted | No REMS stated in release |
💰 SELLAS Cleared at $13.00
SELLAS priced its $150.0 million offering at $13.00 per share, 32.1% below Tuesday's post data close, and answered the question we put on record last night. SLS
The deal held size at 11,538,462 shares plus a roughly 15% option, with J.P. Morgan, TD Cowen and Mizuho on the books and closing expected Friday. We wrote Tuesday that the clearing price, not the close, would be the real grade of the REGAL data, and the grade came in at a 32.1% discount (our arithmetic): the counting standard still rules. The other half of the verdict is that $13.00 remains 74.0% above Monday's pre data close, so the survival data bought real capital, just not Tuesday's price. The stock slipped 6.3% to $17.95 during the bookbuild; pricing crossed after hours, which makes Thursday the first post pricing session.
📄 The FDA Posted Summit's Rejection Letter
The FDA published its ivonescimab complete response letter within days of the decision, and the letter reads heavier than Summit's version of it. SMMT
Per BioPharma Dive, the November 13 letter calls the benefits modest, says they do not outweigh additive safety risks, questions how relevant the data are to US patients, and tells Summit a new trial is needed. Summit's Sunday statement had framed the rejection as a missing survival benefit. Leerink's Daina Graybosch wrote that a resubmission alone is unlikely to change the outcome. Summit closed at $10.50, now 36.9% below its November 11 close (our arithmetic). We did not retrieve the letter itself; the characterizations are attributed to the trade reports of it.
🤝 Lilly and Biogen Bought Discovery on the Biobucks Plan
Eli Lilly signed a cancer discovery alliance with Stipple Bio worth up to $5.9 billion, and Biogen paid over $32 million upfront for Trimtech's CNS penetrant protein degraders. LLY | BIIB
Lilly gets Stipple's platform for finding molecules that bind epitopes present only on tumor cells, for an undisclosed upfront plus an equity stake; Biogen's deal adds up to $411 million in milestones and an option to exclusive licenses on whatever the degrader work produces. Both sets of figures are per BioPharma Dive; neither company release surfaced in our sweep. Small guaranteed checks against very large ceilings is what discovery stage dealmaking looks like this year, and Wednesday put neurodegeneration and tumor selectivity, two of the hardest discovery problems in the industry, on the same day's tape.
📋 Quick Hits
Teva's head of R&D Eric Hughes is departing, announced at 5:00 pm Wednesday, one week after the R&D Day that laid out its 2030 innovative pipeline targets. Thursday is the first session to price it. TEVA
InspireMD completed the first US commercial TCAR procedures with its FDA approved CGuard Prime carotid stent system, announced after Wednesday's close. NSPR
Biogen and Ionis say diranersen showed increasing clinical benefit at two years in early Alzheimer's disease; the headline carried no figures, and the first reaction was a shrug (BIIB +0.2%, IONS +1.6%). BIIB | IONS
BioXcel is four days past the November 14 action date on the Igalmi at home sNDA with no announced decision (searches through Wednesday night; we keep checking every build). BTAI
Verified absences, with scope: no CagriSema decision (searches surface only the December 2025 submission; the Q4 window stays open), and nothing new on the 340B rebate pilot v2 docket, where Wednesday's searches surfaced only the February 2026 rulings on the earlier pilot, a different case.
👀 What To Watch Today
Thu, Nov 19: Biohaven's BHV-1530 oral presentation at EORTC-NCI-AACR; Pyxis Oncology's MICVO Phase 1 webcast, Biohaven | Pyxis
Fri, Nov 20: SELLAS' offering is expected to close; Capricor's deramiocel window opens ahead of the Sunday action date, SELLAS | Capricor
Mon, Nov 30: Double PDUFA, Vertex's povetacicept in IgAN and the lidERA adjuvant giredestrant decision, Vertex | Roche
📖 In Today's Full Analysis
Be sure to read the full article for all the details, including:
The complete NIMBLE and PREVAIL tables, endpoint by endpoint
The SELLAS offering terms and the discount math against all three reference prices
What the FDA's ivonescimab letter says, as reported, and who said it
The movers table with context, from Merck's first BTK free session to GSK's Nelkarmi reaction
🔒 BioMed Nexus Pro
In Today's Pro Brief...
🧠 The gMG modality ladder: why AstraZeneca just flanked its own franchise, and who pays for four needles a year
💊 The clearing price verdict: what $13.00 tells every CFO holding a Phase 3 readout
📊 The rejection letter era: what the FDA posting CRLs in days changes for sponsors
🎯 Plus the week's coming catalysts, with the full calendar returning in Friday's edition

